GFRAL

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 11, 2024
Research, GDF15, PSC, Part, Vomiting, Pregnancy, MSS, Liver, Atlas, Preterm birth, NGM, LAIR1, Nausea, Hospital, ILT3, GFRAL, Food and Drug Administration, NASH, Therapy, Woman, Toxicology, Liver disease, CRC, Cirrhosis, Biomarker, Place of birth, Colorectal cancer, Agreement, Acquisition, Plan, FGF19, AASLD, FDA, Food, Weight loss, Primary sclerosing cholangitis, Pembrolizumab, Dehydration, Bile, Hyperemesis gravidarum, HG, Patient, Pre-eclampsia, Malnutrition, Pharmaceutical industry

--On February 26, 2024, announced that it had entered into the Agreement and Plan of Merger with Atlas Neon Parent, Inc., and Atlas Neon Merger Sub, Inc.--

Key Points: 
  • The combination of NGM707 and pembrolizumab was generally well-tolerated at all four doses (200, 600, 1200, 1800 mg) of NGM707.
  • Additional details can be found in NGM Bio’s recent filings with the United States Securities and Exchange Commission (SEC).
  • NGM Bio anticipates that the Offer and the Merger contemplated under the Merger Agreement will be consummated in the second quarter of 2024.
  • If the Merger is effected, NGM Bio’s common stock will be delisted from The Nasdaq Stock Market LLC and NGM Bio will be privately held.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024
Liver, School, Liraglutide, Metformin, SCM, GDF15, HKBU, Artesunate, Multimedia, Research, Blood, Obesity, FDA, Fatty liver disease, Exercise, Nausea, Food, GDNF, Trial of the century, Health, Human, Safety, GFRAL, Associate, Patient, Fasting, Insulin, Nature Communications, Tissue, Appetite, Hong Kong Baptist University, Mouse, Public, Pharmaceutical industry

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024
Liver, School, Liraglutide, Metformin, SCM, GDF15, HKBU, Artesunate, Research, Blood, Obesity, FDA, Fatty liver disease, Exercise, Nausea, Food, GDNF, Trial of the century, Health, Human, Safety, GFRAL, Associate, Patient, Fasting, Insulin, Nature Communications, Tissue, Appetite, Hong Kong Baptist University, Mouse, Public, Pharmaceutical industry

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need

Retrieved on: 
Tuesday, January 9, 2024
Bile, Woman, Hyperemesis gravidarum, Research, Biology, Hospital, Weight loss, MSS, FRS, Hepatology, University, ILT3, Liver disease, FGF19, GFRAL, LAIR1, Liver, Doctor of Philosophy, NASH, CRC, Pembrolizumab, Trial of the century, Neoplasm, NGM, SAN, PRS, Public health, Genetic epidemiology, Preterm birth, Vomiting, Cirrhosis, DCR, Dehydration, AASLD, Immunotherapy, Place of birth, Medicine, Pregnancy, Pre-eclampsia, Therapy, ELF, Patient, Bile acid malabsorption, Fibrosis, Nausea, Alkaline phosphatase, PSC, Gastrointestinal disease, CRN, IBS-D, Malnutrition, FDA, Biomarker, Pharmaceutical industry

NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.

Key Points: 
  • NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.
  • Recent landmark genetic research confirmed the link between this rare, devastating condition experienced during pregnancy to higher levels of GDF15.
  • Given our deep expertise in GDF15 biology, we believe we are well positioned to potentially pursue this indication for NGM120.
  • NGM Bio previously reported data from a randomized, double-blind, placebo-controlled Phase 2 study of aldafermin for the treatment of PSC.

NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities

Retrieved on: 
Monday, January 9, 2023
Congress, Merck, Retina, AML, GFRAL, Multiple myeloma, NGM, Geographic atrophy, Safety, ILT3, C3, FGF19, ASH, LAIR1, Conference, GDF15, Week, ESMO, AACR, Therapy, Patient, Drug discovery, Macular degeneration, European Society for Medical Oncology, Cancer, SAN, Society, Pancreatic cancer, NASH, Pembrolizumab, Medical imaging, Fine chemical, Pharmaceutical industry, Vaccine

“In 2022, NGM Bio sharpened its focus on oncology solid-tumor clinical development.

Key Points: 
  • “In 2022, NGM Bio sharpened its focus on oncology solid-tumor clinical development.
  • Dr. Woodhouse continued, “Our strategy in 2023 is to focus our clinical development efforts on our portfolio of four clinical-stage oncology programs while operating our prolific drug discovery engine to generate next-generation biologic therapeutics.
  • For our programs outside this area of focus, in retinal disease and NASH, we will seek development partners with relevant domain expertise.
  • Presented additional findings from post-hoc analyses from the CATALINA trial at The Retina Society Annual Scientific Meeting in Q4 2022.

NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting

Retrieved on: 
Wednesday, December 7, 2022
Neoplasm, Retina, RO, PR, COVID-19, Pneumonitis, Liver, Tumor microenvironment, Health, Safety, Congress, Cancer, European Society for Medical Oncology, Protein engineering, ILT3, ILT2, GFRAL, Trae tha Truth, Biology, Therapy, LIR, Merck, LILRB4, ILT, RECIST, Translation, Oncology, Disease, Patient, ILT4, ESMO, Linearity, Cell, Failure, LAIR1, NGM, Myelocyte, G5, Merck Sharp & Dohme Federal Credit Union, Part, CD163, Merck & Co., Risk, Pharmaceutical industry, Vaccine

The Phase 1 portion of the ongoing NGM707 trial includes a monotherapy dose escalation arm (Part 1a) and a dose-finding arm in combination with pembrolizumab (KEYTRUDA®) (Part 1b).

Key Points: 
  • The Phase 1 portion of the ongoing NGM707 trial includes a monotherapy dose escalation arm (Part 1a) and a dose-finding arm in combination with pembrolizumab (KEYTRUDA®) (Part 1b).
  • The Phase 2 portion of the trial will include expansion cohorts of patients treated with NGM707 in combination with KEYTRUDA (Part 2b) in several advanced solid tumor types.
  • The Part 1a arm enrolled patients into escalating NGM707 dose cohorts (6 mg to 1800 mg) administered intravenously every three weeks.
  • As of a November 23, 2022 data cut-off, 34 patients have been enrolled in the monotherapy dose escalation.

NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
MSD, Private Securities Litigation Reform Act, GDF15, Biology, FGF19, Bias, GFRAL, Failure, U.S. Securities and Exchange Commission, Disease, SEC, SAN, Congress, GLOBE, Fatty liver disease, Retina, NGM, Health, Geographic atrophy, Prostate cancer, Patient, Cancer, Protein engineering, Research, ILT3, Merck & Co., COVID-19, Pancreatic cancer, Cirrhosis, Therapy, LAIR1, NASH, Conference, Nasdaq, Risk, Merck Sharp & Dohme Federal Credit Union, Pembrolizumab, AACR, Liver, Pharmaceutical industry, Medical imaging, Merck

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the quarterly period ended September 30, 2022. 

Key Points: 
  • MK-3655 is an agonistic antibody product candidate binding to fibroblast growth factor receptor 1c-beta-klotho that Merck licensed from NGM Bio.
  • NGM Bio reported a net loss of $47.3million for the quarter ended September30, 2022, compared to a net loss of $28.9 million for the same period in 2021.
  • R&D expenses were $46.1million for the quarter ended September30, 2022, compared to $38.7million for the same period in 2021.
  • NGM Bio expects its cash, cash equivalents and marketable securities will be sufficient to fund its planned operations into the fourth quarter of 2024.

NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer

Retrieved on: 
Tuesday, September 13, 2022
Lists of diseases, Therapy, American Association for Cancer Research, Particle-size distribution, Health, AACR, Trial of the century, COVID-19, Pancreatic cancer, Prostate, Population, Senior, GFRAL, Private Securities Litigation Reform Act, Retina, Melanoma, American Association, GDF15, Patient, Cancer, U.S. Securities and Exchange Commission, Prognosis, Protein engineering, NGM, Biology, Serum, Nasdaq, Progression-free survival, Liver, MCRPC, Failure, Conference, Large-cell lung carcinoma, Association, GLOBE, SEC, Annual report, Disease, Pharmaceutical industry

The abstracts first author, Andrew Hendifar, M.D., Cedars-Sinai, Samuel Oschin Cancer Center, commented, The preliminary disease control results observed with NGM120 in combination with gemcitabine/Nab-paclitaxel in the Phase 1b cohort merit attention.

Key Points: 
  • The abstracts first author, Andrew Hendifar, M.D., Cedars-Sinai, Samuel Oschin Cancer Center, commented, The preliminary disease control results observed with NGM120 in combination with gemcitabine/Nab-paclitaxel in the Phase 1b cohort merit attention.
  • While a small sample size, seeing two patients in this cohort exhibit partial response beyond 17 months is intriguing.
  • NGM Bio scientists have made several important discoveries related to GDF15, including identification of its cognate receptor, GFRAL.
  • NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease.

NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress

Retrieved on: 
Tuesday, September 6, 2022
European Society for Medical Oncology, Prostate cancer, COVID-19, Cancer, Retina, PSA, Lists of diseases, Large-cell lung carcinoma, Liver, Disease, Sharp Grossmont Hospital, Financial toxicity, Serum, ESMO, Senior, Prognosis, MCRPC, SEC, Particle-size distribution, NGM, U.S. Securities and Exchange Commission, GLOBE, Protein engineering, Patient, Prostate-specific antigen, Biology, Nasdaq, Therapy, GDF15, Oncology, Failure, Prostate, Congress, GFRAL, Annual report, Melanoma, Private Securities Litigation Reform Act, Health, Trial of the century, Ministry of Education (Malaysia), Pharmaceutical industry, Medical imaging

We are pleased to share these updated findings from the Phase 1a dose escalation trial of NGM120, said Alex DePaoli, M.D., Senior Vice President, Chief Translational Officer at NGM Bio.

Key Points: 
  • We are pleased to share these updated findings from the Phase 1a dose escalation trial of NGM120, said Alex DePaoli, M.D., Senior Vice President, Chief Translational Officer at NGM Bio.
  • While still preliminary, these findings provide an interesting signal that encourages further study of NGM120 for the treatment of patients with advanced prostate cancer.
  • NGM Bio scientists have made several important discoveries related to GDF15, including identification of its cognate receptor, GFRAL.
  • NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease.

NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial o

Retrieved on: 
Monday, August 15, 2022
Liver, U.S. Securities and Exchange Commission, Prostate cancer, Science, Failure, Private Securities Litigation Reform Act, SEC, Cancer, Protein engineering, Plenary session, COVID-19, GFRAL, AACR, Biology, NGM, Patient, Conference, Annual report, Retina, Health, Lists of diseases, Disease, Pancreatic cancer, Pharmaceutical industry

All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need.

Key Points: 
  • All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need.
  • Today, the company has seven programs in clinical development,including four in Phase 2 or 2b studies,across three therapeutic areas: cancer, retinal diseases and liver and metabolic diseases.
  • Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • Except as required by law, NGM Bio assumes no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.